References
- Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096–103.
- Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008;58(4):953–63.
- Westovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12):1870–77
- Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007;19(3):238–45.
- Ogasawara M, Tamura N, Kageyama M, Onuma S, Kusaoi M, Toyama S, et al. Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis. Clin Rheumatol. 2012;31(2):251–7.
- Takakubo Y, Tamaki Y, Hirayama T, Iwazaki K, Yang S, Sasaki A, et al. Mid-term clinico-radiologic findings of an open-label observation study of add-on tacrolimus with biologic or non-biologic DMARDs. Rheumatol Int. 2012;32(11):3487–94.
- Miyata M, Asano T, Satoh S. Effect of additional administration of tacrolimus in patients with rheumatoid arthritis treated with biologics. Fukushima J Med Sci. 2011;57(2):54–9.
- Mori S. Additional use of tacrolimus after switching to tocilizumab therapy in patients with primary lack of efficacy of infliximab therapy for rheumatoid arthritis. Mod Rheumatol. 2012;22(6):947–50.
- Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, et al. Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study. Mod Rheumatol. 2012;22(3):339–45.
- McInnes IB, Schett G. The Pathogenesis of Rheumatoid Arthritis. N Engl J Med. 2011;365(23):2205–19.
- Carman JA, Davis PM, Yang WP, Zhu J, Chang H, He A, et al. Abatacept does not induce direct gene expression changes in antigen-presenting cells. J Clin Immunol. 2009;29(4):479–89.
- Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S, et al. FK506 potently inhibits T cell activation induced TNF-α and I-1β production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130(7):1655–63.
- Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S. Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflamm Res. 2004;53(10):544–50.
- Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, et al. Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients. Mod Rheumatol. 2013;23(5):904–12.